Work

Outcomes for patients with platinum-sensitive recurrent ovarian cancer treated with prolonged PARP inhibitor therapy.

Year: 2025

Type: conference-abstract

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e17607

Authors: Corrine A. Nief, Jonathan S. Berek, Talayeh Ghezelayagh

Institutions: Stanford Medicine, Stanford University, Stanford Cancer Institute

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410811828

Cites:

Cited by:

Related to: 10